Heading the second Cambridge site
UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the companys US business development and for establishing a team in the US.
Bicycle Therapeutics is a biotechnology company developing a new class of therapeutics based on its proprietary bicyclic peptides platform, headquartered in Cambridge, UK. Deeagan joins from Trevena, where she held the position of Senior VP Business development and Operations. Previously, she worked at GlaxoSmithKline. Deegan graduated from Cambridge University and holds an MBA from French business school INSEAD.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium